Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study

Marcia Cruz-Correa, Rui-Hua Xu, Markus Moehler, Do-Youn Oh, Ken Kato, David Spigel, Hendrik-Tobias Arkenau, Josep Tabernero, Anastasia V. Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Hidekazu Hirano, Lucjan Wyrwicz, Roberto Pazo Cid, Hui Xu, Tao Sheng, Gisoo Barnes

Open source

DOI: 10.1080/03007995.2025.2501588
Published: 2025-06-03
Container: Current Medical Research and Opinion
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/03007995.2025.2501588,
  title = {Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study},
  author = {Marcia Cruz-Correa and Rui-Hua Xu and Markus Moehler and Do-Youn Oh and Ken Kato and David Spigel and Hendrik-Tobias Arkenau and Josep Tabernero and Anastasia V. Zimina and Yuxian Bai and Jianhua Shi and Keun-Wook Lee and Hidekazu Hirano and Lucjan Wyrwicz and Roberto Pazo Cid and Hui Xu and Tao Sheng and Gisoo Barnes},
  year = {2025},
  journal = {Current Medical Research and Opinion},
  doi = {10.1080/03007995.2025.2501588},
  url = {https://doi.org/10.1080/03007995.2025.2501588}
}

RIS

TY  - JOUR
TI  - Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study
AU  - Marcia Cruz-Correa
AU  - Rui-Hua Xu
AU  - Markus Moehler
AU  - Do-Youn Oh
AU  - Ken Kato
AU  - David Spigel
AU  - Hendrik-Tobias Arkenau
AU  - Josep Tabernero
AU  - Anastasia V. Zimina
AU  - Yuxian Bai
AU  - Jianhua Shi
AU  - Keun-Wook Lee
AU  - Hidekazu Hirano
AU  - Lucjan Wyrwicz
AU  - Roberto Pazo Cid
AU  - Hui Xu
AU  - Tao Sheng
AU  - Gisoo Barnes
PY  - 2025
JO  - Current Medical Research and Opinion
DO  - 10.1080/03007995.2025.2501588
UR  - https://doi.org/10.1080/03007995.2025.2501588
ER  -

APA

Cruz-Correa, M., Xu, R., Moehler, M., Oh, D., Kato, K., Spigel, D., Arkenau, H., Tabernero, J., Zimina, A. V., Bai, Y., Shi, J., Lee, K., Hirano, H., Wyrwicz, L., Cid, R. P., Xu, H., Sheng, T., & Barnes, G. (2025). Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2025.2501588

Source records

crossref · retrieved 2026-09-26T06:30:55.665Z